🔗 Share this article

While the US undertakes sweeping changes to its immunization recommendations, an unexpected name has emerged unexpectedly: Tracy Beth Høeg, a US-based physician and epidemiologist who rose to prominence by questioning coronavirus vaccines throughout the global health crisis and has concentrated on alleged fatalities following COVID-19 immunization in her recent position at the US Food and Drug Administration (FDA).

Proposed Overhauls to Pediatric Immunization Program

Agency leaders planned to reveal radical changes to the pediatric vaccine schedule in December, aligning the US with the Danish national calendar, sources say – a significant shift that would put the US out of step with a large portion of the international standard with little proof for improved outcomes. The planned update has been postponed until the coming year.

Instead of the director of the vaccine center, Tracy Beth Høeg is set to address the audience at the event. She was recently named interim head of the FDA’s drug evaluation center, the fifth person to lead the division this year.

A New Direction at the Regulatory Body

The acting appointment could signify a tighter collaboration between the pharmaceutical and vaccine centers as Høeg and Dr. Prasad strengthen their influence at the FDA – and it points to a renewed priority upon reevaluating already-approved immunizations at the FDA.

Høeg has often pushed for halting specific pediatric vaccine recommendations in the US so as to align more like the Danish model, a country with nationalized medicine and a population roughly the size of Wisconsin’s.

To date statements, she has continued to focus on vaccination policy – traditionally the domain of Prasad, head of the FDA’s vaccine center – as opposed to drug regulation.

Concerns Over Expertise

The appointee has no apparent track record in pharmaceutical research, regulation or management, which has been customary for past directors of the CBER. She has served at the FDA as a top consultant to the FDA chief and CBER since March.

“She doesn’t seem to have any of the qualifications” for leading the drug-regulation department, remarked Jonathan Howard. “She has not conducted a scientific study. She is not versed in running a major agency. She has no expertise in pharmaceutical oversight.”

Previous commissioners of CBER would “understand legal statutes and the underlying principles of pharmaceutical innovation”, noted a former acting FDA commissioner. “Clearly, she lacks the sort of resume that prior appointees who led CBER have had.”

The drug center has an vast range of responsibilities at the agency, she emphasized.

“The public just pays attention on the new drug program, but the generic drug division approves a multitude of generic drugs. There’s a biologic copycat branch, non-prescription drug unit and more, and every single one need to be supervised,” Woodcock noted. “The area you overlook, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a major management aspect to the position, which manages in excess of 5,000 staff members. “It is a huge administrative position, if you execute it properly,” Woodcock added.

Response and Disputed Policies

Regarding questions about Høeg’s fitness for the role and whether this assignment represents increased cooperation among FDA leaders on immunizations, a representative stated that the “concerns stem from inaccurate premises”.

“Her resume aligns with the responsibilities of her position,” the representative stated, pointing to the months Høeg spent counseling the agency head on “pharmaceutical safety and approval science, including computational safety modeling and shot safety tracking”.

As the temporary head, Dr. Høeg assumes responsibility for the commissioner’s recently launched priority voucher program, a controversial one-day medication authorization process that reportedly worried her predecessors. “How are these medications being picked for this expedited pathway? Who is making the calls?” Howard asked. “There is a lot of confidentiality happening at the regulatory body right now.”

In general, he stated, “the agency looks to be trending towards laxer rules of most medications, with the exception of immunizations.”

Established History on Immunizations

Concerning vaccines, Dr. Høeg has a more established, if troubling, track record, some experts have noted. She released a research paper using unverified public submissions to estimate the frequency of heart inflammation after Covid immunization. She counseled the state of Florida surgeon general Joseph Ladapo, who reportedly have modified findings to suggest Covid vaccinations are pose a greater threat than they are.

Part of her “desired changes” for the current administration featured revising guidelines for recently developed shots and ending “unnecessary” immunizations, she stated post-election on a audio program. At the FDA, Dr. Høeg has reportedly proposed barring young men from receiving COVID-19 vaccines.

“She’s an complete true believer who starts off with her conclusions and tailors the evidence to accommodate the science in a very deceptive, fraudulent fashion,” Dr. Howard stated.

Consolidating Power and a “Revenge Tour”

Dr. Høeg became part of other contrarians, {like|